Incyte FDA Wednesday, November 16, 2011 +0.80 Positive

FDA Approves JAKAFI — Incyte Corporation

Incyte Corporation announced the approval of the oral JAK inhibitor ruxolitinib under the brand name JAKAFI for [specific indication, e.g., the treatment of moderate to severe atopic dermatitis or polycythemia vera], significantly broadening the reach of its multi-billion dollar JAK inhibitor franchise and strengthening its competitive position against rival inhibitors in the growing targeted therapy landscape.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed